North Dakota Clinical Trials

Recruiting studies in North Dakota

• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
  NCT06172296Ganglioneuroblastoma, NodularFargo, ND
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
  NCT06064097Stage II Nasopharyngeal Carcinoma AJCC v8Fargo, ND
• KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
  NCT04165798Carcinoma, Non-Small-Cell LungFargo, ND
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060Heart FailureFargo, ND
• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
  NCT04166409Low Grade AstrocytomaFargo, ND
• Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
  NCT07061964Muscle Invasive Bladder Urothelial CarcinomaFargo, ND
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
  NCT06770582Non-Muscle Invasive Bladder Urothelial CarcinomaFargo, ND
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
  NCT05112601Endometrial AdenocarcinomaFargo, ND
• Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
  NCT05001880Peritoneal Malignant MesotheliomaBismarck, ND
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
  NCT06077760Non-small Cell Lung CancerFargo, ND
• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
  NCT06577441Myelodysplastic SyndromeFargo, ND
• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
  NCT06890338Epithelial Ovarian CancerFargo, ND

See all 147 recruiting North Dakota trials →

Popular conditions in North Dakota

• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Colorectal Cancer
• Obesity
• Type 2 Diabetes
• Depression
• Alzheimer Disease
• Heart Failure
• Multiple Sclerosis
• Rheumatoid Arthritis
• Asthma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Frequently asked questions

How do I find clinical trials in North Dakota?

Corterve aggregates actively recruiting clinical trials with sites in North Dakota from the public ClinicalTrials.gov registry. Browse the studies on this page or take a free health assessment to find trials you may qualify for.

Are clinical trials in North Dakota free to join?

Study participation is typically free — sponsors cover the investigational treatment and study-related visits, and many studies compensate participants for time and travel. Details vary by study.

What kinds of clinical trials are available in North Dakota?

North Dakota research sites run studies across many areas including oncology, neurology, cardiology, and metabolic health. This page is general information and not medical advice; confirm any specific trial with your healthcare provider.